Spectranetics Announces Fourth Quarter 2016 Conference Call
February 02, 2017 16:01 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Feb. 02, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC), today announced that the Company will release fourth quarter 2016 financial results on...
ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations
January 24, 2017 05:00 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Jan. 24, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that Professor Thomas Zeller presented the final 12-month...
Spectranetics Names Scott Hutton as General Manager, Vascular Intervention
January 11, 2017 09:00 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Jan. 11, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that Scott Hutton has been named General Manager, Vascular...
Spectranetics to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 28, 2016 16:05 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Dec. 28, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the 35th Annual J.P. Morgan...
Spectranetics Receives CE Mark for Stellarex™ 0.014” Drug-Coated Balloon
November 21, 2016 16:05 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 21, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that its Stellarex™ 0.014” Drug-coated Angioplasty Balloon (DCB) has received...
Spectranetics to Attend Upcoming Investor Conferences
November 07, 2016 09:00 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 07, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that company management will be attending three upcoming...
Stellarex™ ILLUMENATE Pivotal Results Are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials
November 02, 2016 09:15 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Sean Lyden presented the final 12-month results of the Stellarex...
Spectranetics Files PMA Application for FDA Approval of the Stellarex™ Drug-Coated Balloon
November 02, 2016 08:00 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) announced today that it has submitted to the Food & Drug Administration (FDA) its...
Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million
October 27, 2016 16:01 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Oct. 27, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended September 30, 2016. ...
Spectranetics Announces Third Quarter 2016 Conference Call and Upcoming Webcast at the Transcatheter Cardiovascular Therapeutics Conference
October 06, 2016 16:05 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Oct. 06, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release third quarter 2016 financial results after the...